EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Progress on the development of Class A GPCR‐biased ligands

Paula Morales, Magdalena M Scharf iD, Marcel Bermudez iD, Attila Egyed, Rafael Franco iD, Olivia K Hansen, Nadine Jagerovic, Jan Jakubík iD, György M Keserű, Dóra Judit Kiss, Pawel Kozielewicz iD, Olav Larsen und 9 weitere

British Journal of Pharmacology · 2025

DOI: 10.1111/bph.17301 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift British Journal of Pharmacology, 2025. Verfasst von Paula Morales und 20 weiteren Autor:innen. Beteiligte Einrichtung: Instituto de Química Médica, Consejo Superior de Investigaciones Científicas, Madrid, Spain. Hauptthemen laut MEDLINE: Receptors, G-Protein-Coupled, Drug Discovery. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 231 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Office of Research, Development and Innovation, Ministerio de Ciencia e Innovación, Cancerfonden.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Class A G protein‐coupled receptors (GPCRs) continue to garner interest for their essential roles in cell signalling and their importance as drug targets. Although numerous drugs in the clinic target these receptors, over 60% GPCRs remain unexploited. Moreover, the adverse effects triggered by the available unbiased GPCR modulators, limit their use and therapeutic value. In this context, the elucidation of biased signalling has opened up new pharmacological avenues holding promise for safer therapeutics. Functionally selective ligands favour receptor conformations facilitating the recruitment of specific effectors and the modulation of the associated pathways. This review surveys the current drug discovery landscape of GPCR‐biased modulators with a focus on recent advances. Understanding the biological effects of this preferential coupling is at different stages depending on the Class A GPCR family. Therefore, with a focus on individual GPCR families, we present a compilation of the functionally selective modulators reported over the past few years. In doing so, we dissect their therapeutic relevance, molecular determinants and potential clinical applications. LINKED ARTICLES This article is part of a themed issue Complexity of GPCR Modulation and Signaling (ERNST). To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v182.14/issuetoc

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, G-Protein-CoupledDrug DiscoveryHumansLigandsAnimalsSignal TransductionDrug Development

Stichwörter der Autor:innen

G protein‐coupled receptorsGPCR modulatorsbiased signallingfunctionally selective ligands

Substanzen

Receptors, G-Protein-CoupledLigands

Autor:innen und Institutionen

  • Instituto de Química Médica, Consejo Superior de Investigaciones Científicas, Madrid, Spain.
  • Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
  • Institute for Pharmaceutical and Medicinal Chemistry, University of Münster, Münster, Germany.
  • Medicinal Chemistry Research Group and National Drug Discovery and Development Laboratory, Research Centre for Natural Sciences, Budapest, Hungary.
  • Molecular Neurobiology Laboratory, Department of Biochemistry and Molecular Biology, Universitat de Barcelona, Barcelona, Spain.
  • CiberNed. Network Center for Neurodegenerative Diseases, National Spanish Health Institute Carlos III, Madrid, Spain.

ORCID-Profile: Magdalena M Scharf, Marcel Bermudez, Rafael Franco, Jan Jakubík, Pawel Kozielewicz, Gemma Navarro, Mette M Rosenkilde, Holger Stark

Förderung

  • National Office of Research, Development and Innovation
  • Ministerio de Ciencia e Innovación
  • Cancerfonden
  • NIH HHS
  • German Research Foundation
  • Swedish Society for Medical Research
  • Hungarian Academy of Sciences
  • Consellería de Cultura, Educación e Ordenación Universitaria of the Galician Government

Zitieren

APA

Morales, P., Scharf, M. M., Bermudez, M., Egyed, A., Franco, R., Hansen, O. K., Jagerovic, N., Jakubík, J., Keserű, G. M., Kiss, D. J., Kozielewicz, P., Larsen, O., Majellaro, M., Mallo-Abreu, A., Navarro, G., Prieto-Díaz, R., Rosenkilde, M. M., Sotelo, E., Stark, H., …, & Wingler, L. M. (2025). Progress on the development of Class A GPCR‐biased ligands. British Journal of Pharmacology. https://doi.org/10.1111/bph.17301

Vancouver

Morales P, Scharf MM, Bermudez M, Egyed A, Franco R, Hansen OK, et al. Progress on the development of Class A GPCR‐biased ligands. British Journal of Pharmacology. 2025. doi:10.1111/bph.17301

BibTeX
@article{Morales2025,
  author = {Morales, Paula and Scharf, Magdalena M and Bermudez, Marcel and Egyed, Attila and Franco, Rafael and Hansen, Olivia K and Jagerovic, Nadine and Jakubík, Jan and Keserű, György M and Kiss, Dóra Judit and Kozielewicz, Pawel and Larsen, Olav and Majellaro, Maria and Mallo-Abreu, Ana and Navarro, Gemma and Prieto-Díaz, Rubén and Rosenkilde, Mette M and Sotelo, Eddy and Stark, Holger and Werner, Tobias and Wingler, Laura M},
  title = {Progress on the development of Class A GPCR‐biased ligands},
  journal = {British Journal of Pharmacology},
  year = {2025},
  doi = {10.1111/bph.17301}
}
Kostenlos starten →